BOVIE MEDICAL CORPORATION TO RELEASE FIRST QUARTER 2017 FINANCIAL RESULTS ON MAY 15, 2017
CLEARWATER, FL – April 26, 2017 – Bovie Medical (BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that financial results for the first quarter of 2017 will be released after the market closes on Monday, May 15.
Management will host a conference call at 4:30 p.m. Eastern Time on May 15 to discuss the results of the quarter and host a question and answer session. To listen to the call by phone, interested parties within the U.S. may dial 866-682-6100. International callers may dial 862-255-5401. Participants should ask for the Bovie Medical Corporation Call. A live webcast of the call will be accessible via the Investor Relations section of the Company’s website and at: http://www.investorcalendar.com/IC/CEPage.asp?ID=175894.
A telephonic replay will be available approximately two hours after the end of the call through June 15, 2017. The replay can be accessed by dialing 877-481-4010 for U.S. callers or 919-882-2331 for International callers and using the replay access code: 10357. The webcast will be archived on the Investor Relations section of the Company’s website.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, IDS™, ICON™ and DERMTM) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation at www.boviemed.com.
Mike Piccinino, CFA